Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728945 | 0.83 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL21395235 | 0.82 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL2306577 | 0.82 | MAPT (0.55) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL2890719 | 0.80 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL5149093 | 0.78 | L3MBTL1 (0.48) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL2898384 | 0.77 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL21384024 | 0.76 | MARS1 (0.43) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL21383972 | 0.76 | PTGS2 (0.44) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7858483 | 0.76 | TSHR (0.66) | ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2 | |
| SCHEMBL11330723 | 0.75 | KDM4E (0.37) | ALDH1A1L3MBTL1MAPTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461160-B2 | Dihydropyrimidinones | HOFFMANN-LA ROCHE, INC. (US) | 2013-06-11 | — | — | US | claimed |
| CN-102421760-A | Dihydropyrimidinones useful as BACE2 inhibitors | HOFFMANN LA ROCHE | 2012-04-18 | — | — | CN | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-3768269-B1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-20 | — | — | EP | disclosed |
| US-20250154127-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-07-07 | — | — | US | disclosed |
| EP-2307409-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2009140320-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | ALDH1A1 4350/4885L3MBTL1 4675/4885MAPT 750/4885 |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-20250154127-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP3A43 | ALDH1A1 636/4885L3MBTL1 3596/4885MAPT 3689/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | ALDH1A1 3910/4885L3MBTL1 1232/4885MAPT 2466/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | NTRK1, NTRK3, NTRK2 | ALDH1A1 3613/4885L3MBTL1 1405/4885MAPT 2625/4885 |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | ALDH1A1 2477/4885L3MBTL1 1210/4885MAPT 3579/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | ALDH1A1 3976/4885L3MBTL1 3337/4885MAPT 8/4885 |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | ALDH1A1 563/4885L3MBTL1 4566/4885MAPT 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.